Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)

Zhongyan Wang; Chuanrui Ma; Yuna Shang; Lijun Yang; Jing Zhang; Cuihong Yang; Chunhua Ren; Jinjian Liu; Guanwei Fan; Jianfeng Liu

doi:10.1039/D0CC00513D

Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)†

Zhongyan Wang,

‡^a Chuanrui Ma,‡^b Yuna Shang,^c Lijun Yang,^a Jing Zhang,^b Cuihong Yang,^a Chunhua Ren,

^a Jinjian Liu,

^a Guanwei Fan*^b and Jianfeng Liu

*^a

Author affiliations

* Corresponding authors

^a Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, P. R. China
E-mail: liujianfeng@irm-cams.ac.cn

^b First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome, Tianjin 300381, P. R. China
E-mail: guanwei.fan@tjutcm.edu.cn

^c College of Life Sciences, Nankai University, Tianjin 300071, P. R. China

Abstract

We have developed a co-assembled nanosystem based on fenofibrate and ketoprofen by tactfully utilizing their simultaneous benzophenone interaction, which greatly enhances the bioavailability of fenofibrate and plays a role in the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses.

Chemical Communications

Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)†

Abstract

Supplementary files

Article information

Download Citation

Permissions

Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)

Social activity

Search articles by author

Spotlight

Advertisements